IN2015DN00694A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00694A IN2015DN00694A IN694DEN2015A IN2015DN00694A IN 2015DN00694 A IN2015DN00694 A IN 2015DN00694A IN 694DEN2015 A IN694DEN2015 A IN 694DEN2015A IN 2015DN00694 A IN2015DN00694 A IN 2015DN00694A
- Authority
- IN
- India
- Prior art keywords
- glycoconjugates
- immunogenic compositions
- etec
- tein
- oxoethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684043P | 2012-08-16 | 2012-08-16 | |
PCT/IB2013/056597 WO2014027302A1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00694A true IN2015DN00694A (ru) | 2015-06-26 |
Family
ID=49385307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN694DEN2015 IN2015DN00694A (ru) | 2012-08-16 | 2013-08-12 |
Country Status (30)
Country | Link |
---|---|
US (6) | US9517274B2 (ru) |
EP (2) | EP3421051B1 (ru) |
JP (1) | JP6291495B2 (ru) |
KR (1) | KR101742406B1 (ru) |
CN (1) | CN104661684B (ru) |
AR (1) | AR092368A1 (ru) |
AU (1) | AU2013303826B2 (ru) |
BR (1) | BR112015003227B1 (ru) |
CA (1) | CA2881420C (ru) |
DK (2) | DK2885007T3 (ru) |
ES (2) | ES2700824T3 (ru) |
FR (1) | FR22C1037I2 (ru) |
HK (1) | HK1210021A1 (ru) |
HU (3) | HUE049531T2 (ru) |
IL (1) | IL237066B (ru) |
IN (1) | IN2015DN00694A (ru) |
MX (1) | MX363511B (ru) |
MY (1) | MY167579A (ru) |
NL (1) | NL301188I2 (ru) |
NZ (1) | NZ704490A (ru) |
PE (1) | PE20150464A1 (ru) |
PH (1) | PH12015500243A1 (ru) |
PL (2) | PL3421051T3 (ru) |
PT (2) | PT3421051T (ru) |
RU (2) | RU2645071C2 (ru) |
SA (1) | SA515360035B1 (ru) |
SG (1) | SG11201500566XA (ru) |
SI (2) | SI3421051T1 (ru) |
TW (1) | TWI480049B (ru) |
WO (1) | WO2014027302A1 (ru) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20150464A1 (es) | 2012-08-16 | 2015-04-25 | Pfizer | Proceso de glucoconjugacion y composiciones |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
PT3096786T (pt) * | 2014-01-21 | 2021-08-24 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
BR112016015835B1 (pt) * | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
CA3206112A1 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3443983B1 (en) * | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
SI3116887T1 (sl) | 2014-03-13 | 2021-06-30 | Universitaet Basel | Ogljikohidratni ligandi, ki se vežejo na protitelesa img proti glikoproteinu, ki je povezan z mielinom |
FI3244917T3 (fi) | 2015-01-15 | 2023-05-25 | Pfizer | Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi |
AU2016258284C1 (en) * | 2015-05-04 | 2020-09-03 | Pfizer Inc. | Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
MX2017015985A (es) * | 2015-06-08 | 2018-08-15 | Serum Inst Of India Private Ltd | Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida con los mismos. |
WO2017013548A1 (en) * | 2015-07-21 | 2017-01-26 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
JP6849667B2 (ja) * | 2015-09-16 | 2021-03-24 | ウニヴェルズィテート バーゼル | スフィンゴ糖脂質の糖鎖エピトープに対する抗体に結合する炭水化物リガンド |
JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
SG11201900794PA (en) | 2016-08-05 | 2019-02-27 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
EA039427B1 (ru) | 2016-08-05 | 2022-01-26 | Санофи Пастер Инк. | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция |
EP3506935B1 (en) | 2016-09-02 | 2024-01-10 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
BR112019013475A2 (pt) | 2016-12-30 | 2020-02-27 | Sutrovax, Inc. | Conjugados de polipeptídeo-antígeno com aminoácidos não naturais |
PL3570879T3 (pl) | 2017-01-20 | 2022-06-20 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom |
MX2019014829A (es) * | 2017-06-10 | 2020-08-17 | Inventprise Llc | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
KR20200051003A (ko) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
IL276229B2 (en) | 2018-02-05 | 2024-01-01 | Sanofi Pasteur Inc | A multivalent pneumococcal protein-polysaccharide conjugate preparation |
SG11202006388SA (en) | 2018-02-05 | 2020-07-29 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
EP3768309A4 (en) * | 2018-03-23 | 2021-12-01 | Koranex Capital | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS |
CA3096358A1 (en) | 2018-04-18 | 2019-10-24 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
CA3171864A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
EP4107170A2 (en) | 2020-02-23 | 2022-12-28 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
EP4213870A1 (en) | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
WO2022084852A1 (en) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
IL302362A (en) | 2020-10-27 | 2023-06-01 | Pfizer | ESCHERICHIA COLI preparations and their methods |
US20240000912A1 (en) | 2020-11-04 | 2024-01-04 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
KR20230175284A (ko) | 2021-05-28 | 2023-12-29 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
WO2024110839A2 (en) | 2022-11-22 | 2024-05-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
DK0616034T3 (da) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
JP4235262B2 (ja) | 1997-06-12 | 2009-03-11 | シンエツ・バイオ,インコーポレイテッド | 組換え細菌宿主における非生来細菌性エキソ多糖の産生 |
CN1197618C (zh) | 1998-09-30 | 2005-04-20 | 惠氏控股有限公司 | 突变霍乱全毒素佐剂 |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
PT1355673E (pt) * | 2001-01-23 | 2012-08-31 | Sanofi Pasteur Inc | Vacina meningocócica multivalente preparada com um conjugado de polissacárido e proteína |
CA2449670A1 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
CN1977971A (zh) | 2001-06-07 | 2007-06-13 | 惠氏控股有限公司 | 作为佐剂的霍乱全毒素的突变体形式 |
CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
WO2004031394A2 (en) * | 2002-10-03 | 2004-04-15 | Wyeth Holdings Corporation | Process for preparing monoprotected diols from symmetric diols |
US9296795B2 (en) * | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
DE602005010228D1 (de) * | 2004-04-14 | 2008-11-20 | Wyeth Corp | Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper |
US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
KR101730748B1 (ko) | 2005-04-08 | 2017-04-26 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
DK3017827T3 (en) * | 2005-12-22 | 2019-02-18 | Glaxosmithkline Biologicals Sa | Pneumococcal polysaccharide conjugate VACCINE |
TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
US7605257B2 (en) * | 2006-03-07 | 2009-10-20 | Wyeth | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
WO2007127668A2 (en) | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
CA2692069C (en) * | 2007-06-20 | 2016-10-18 | Baxter Healthcare S.A. | Modified polysaccharides for conjugate vaccines |
RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
US9125951B2 (en) * | 2009-06-22 | 2015-09-08 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
WO2011000958A1 (en) * | 2009-07-03 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
WO2011066291A2 (en) * | 2009-11-24 | 2011-06-03 | Talecris Biotherapeutics, Inc. | Lyophilization methods, compositions, and kits |
MX2013006539A (es) * | 2010-12-10 | 2013-07-22 | Merck Sharp & Dohme | Formulaciones novedosas que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas. |
MX358840B (es) * | 2011-09-07 | 2018-09-05 | Prolynx Llc | Hidrogeles con reticulación biodegradable. |
PE20150464A1 (es) * | 2012-08-16 | 2015-04-25 | Pfizer | Proceso de glucoconjugacion y composiciones |
CA3206112A1 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3443983B1 (en) | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
-
2013
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en active Application Filing
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active IP Right Grant
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es unknown
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243A1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
- 2015-10-30 HK HK15110760.0A patent/HK1210021A1/xx unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
-
2023
- 2023-06-21 US US18/338,961 patent/US20230355735A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00694A (ru) | ||
MX340090B (es) | Analogos de spliceostatina. | |
PH12014502826A1 (en) | Immunoconjugates comprising anti-cd79b antibodies | |
MY170719A (en) | Antibody-drug conjugates | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
EA032986B1 (ru) | Пирролобензодиазепины | |
PH12014502825A1 (en) | Immunoconjugates comprising anti-cd22 antibodies | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
MX2015002482A (es) | Composicion inmunogenica. | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
MX352738B (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos. | |
MX2017002333A (es) | Conjugados novedosos de glicano y uso de los mismos. | |
MY174813A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016005763A (es) | Anticuerpos anti-claudina novedosos y metodos de uso. | |
MY169837A (en) | Immunogenic compositions of staphylococcus aureus antigens | |
MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
WO2014134483A3 (en) | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | |
PH12015502645A1 (en) | Igg4 fc fragment comprising modified hinge region | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
WO2014134486A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
IL269028A (en) | Boronized multifunctional drug-targeting conjugates, their uses and methods of preparation |